You are here

  • Home
  • Archive
  • Volume 11, Issue Suppl 1
  • 1194 Mechanism of action of ivonescimab (AK112/SMT112): a first-in-class tetravalent Fc-silent bispecific antibody with dual blockade of PD-1 and VEGF that promotes cooperative biological effects

Citation Tools

Article menu

Download PDFPDF

Regular and Young Investigator Award Abstracts
Immuno-Conjugates and Chimeric Molecules
1194 Mechanism of action of ivonescimab (AK112/SMT112): a first-in-class tetravalent Fc-silent bispecific antibody with dual blockade of PD-1 and VEGF that promotes cooperative biological effects

Download to a citation manager

Download the citation for this article by clicking on one of the following citation managers:

Cite this article as:
Zhong T, Huang Z, Pang X, et al
1194 Mechanism of action of ivonescimab (AK112/SMT112): a first-in-class tetravalent Fc-silent bispecific antibody with dual blockade of PD-1 and VEGF that promotes cooperative biological effects
Journal for ImmunoTherapy of Cancer 2023;11:doi: 10.1136/jitc-2023-SITC2023.1194